Adma Biologics, Inc.
ADMA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001368514
No open-market purchases or sales by Adma Biologics, Inc. insiders were filed in the last 90 days; 322 institutions reported holding it in 13F filings for Q2 2026, worth $1.70B in total; superinvestors Duquesne Family Office and Fundsmith hold it.
Q4 2022 vs. Q3 2022
How the institutions holding Adma Biologics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 130 | 3 | 160 | +33 |
| Shares | 129.8M | 51.6K | 152.6M | +22.9M (+17.7%) |
| Value | $315.4M | $125.4K | $592.2M | +$276.9M (+87.8%) |
3 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (41)
Institutions that held Adma Biologics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
Sold out (8)
Institutions that held Adma Biologics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Clearline Capital LP | 2,496,297 | $6.07M |
| Tang Capital Management LLC | 992,840 | $2.41M |
| EWG Elevate Inc. | 121,000 | $294.0K |
| Game Plan Financial Advisors, LLC | 41,000 | $100.0K |
| Virtu Financial LLC | 36,123 | $88.0K |
| CenterBook Partners LP | 23,779 | $58.0K |
| Maven Securities LTD | 15,000 | $37.0K |
| J. Goldman & Co LP | 12,000 | $29.0K |
Not filed for Q4 2022 yet (3)
Institutions that held Adma Biologics, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Parian Global Management LP | 50,000 | $122.0K |
| American Portfolios Advisors | 1,000 | $2.43K |
| Wipfli Financial Advisors LLC, | 563 | $1.00K |